{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T14:00:25Z","timestamp":1776261625876,"version":"3.50.1"},"reference-count":30,"publisher":"Spandidos Publications","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,6]]},"DOI":"10.3892\/or.2013.2357","type":"journal-article","created":{"date-parts":[[2013,3,22]],"date-time":"2013-03-22T08:35:26Z","timestamp":1363941326000},"page":"2486-2492","source":"Crossref","is-referenced-by-count":13,"title":["Combined inhibition of the EGFR and mTOR pathways in EGFR wild-type non-small cell lung cancer cell lines with different genetic backgrounds"],"prefix":"10.3892","volume":"29","author":[{"given":"YU","family":"HUANG","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"YU","family":"CHEN","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"QIN","family":"MEI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"YUAN","family":"CHEN","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"SHIYING","family":"YU","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"SHU","family":"XIA","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2013,3,22]]},"reference":[{"key":"key20180107215106_b1-or-29-06-2486","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/nrc2088","article-title":"Epidermal growth factor receptor mutations in lung cancer","volume":"7","author":"Sharma","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"key20180107215106_b2-or-29-06-2486","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/nrclinonc.2010.97","article-title":"Understanding resistance to EGFR inhibitors - impact on future treatment strategies","volume":"7","author":"Wheeler","year":"2010","journal-title":"Nat Rev Clin Oncol"},{"key":"key20180107215106_b3-or-29-06-2486","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1200\/JCO.2005.01.388","article-title":"Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small cell lung cancer patients treated with gefitinib","volume":"23","author":"Han","year":"2005","journal-title":"J Clin Oncol"},{"key":"key20180107215106_b4-or-29-06-2486","first-page":"200","article-title":"Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling","volume":"62","author":"Chakravarti","year":"2002","journal-title":"Cancer Res"},{"key":"key20180107215106_b5-or-29-06-2486","doi-asserted-by":"crossref","first-page":"3788","DOI":"10.1073\/pnas.0409773102","article-title":"ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines","volume":"102","author":"Engelman","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"key20180107215106_b6-or-29-06-2486","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.canlet.2011.07.002","article-title":"Combining an EGFR directed tyrosine kinase inhibitor with autophagy-inducing drugs: a beneficial strategy to combat non-small cell lung cancer","volume":"310","author":"Gorzalczany","year":"2011","journal-title":"Cancer Lett"},{"key":"key20180107215106_b7-or-29-06-2486","doi-asserted-by":"crossref","first-page":"3126","DOI":"10.1200\/JCO.2010.32.2321","article-title":"Phase I\/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumab-based therapy","volume":"29","author":"Morrow","year":"2011","journal-title":"J Clin Oncol"},{"key":"key20180107215106_b8-or-29-06-2486","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1038\/sj.bjc.6604269","article-title":"Inhibition of mTOR pathway by everolimus cooperates with EGFR inhibitors in human tumours sensitive and resistant to anti-EGFR drugs","volume":"98","author":"Bianco","year":"2008","journal-title":"Br J Cancer"},{"key":"key20180107215106_b9-or-29-06-2486","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/nrm3025","article-title":"mTOR: from growth signal integration to cancer, diabetes and ageing","volume":"12","author":"Zoncu","year":"2010","journal-title":"Nat Rev Mol Cell Biol"},{"key":"key20180107215106_b10-or-29-06-2486","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1126\/science.1208071","article-title":"Cell signaling. New mTOR targets Grb attention","volume":"332","author":"Yea","year":"2011","journal-title":"Science"},{"key":"key20180107215106_b11-or-29-06-2486","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/nrd2924","article-title":"Everolimus","volume":"8","author":"Atkins","year":"2009","journal-title":"Nat Rev Drug Discov"},{"key":"key20180107215106_b12-or-29-06-2486","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1158\/1535-7163.MCT-09-1014","article-title":"Dependence on phosphoinositide 3-kinase and RAS-RAF pathways drive the activity of RAF265, a novel RAF\/VEGFR2 inhibitor, and RAD001 (Everolimus) in combination","volume":"9","author":"Mordant","year":"2010","journal-title":"Mol Cancer Ther"},{"key":"key20180107215106_b13-or-29-06-2486","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.tiv.2007.03.003","article-title":"A mathematical approach to study combined effects of toxicants in vitro: evaluation of the Bliss independence criterion and the Loewe additivity model","volume":"21","author":"Goldoni","year":"2007","journal-title":"Toxicol In Vitro"},{"key":"key20180107215106_b14-or-29-06-2486","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1186\/1471-2407-6-277","article-title":"Gefitinib (Iressa) sensitive lung cancer cell lines show phosphorylation of Akt without ligand stimulation","volume":"6","author":"Noro","year":"2006","journal-title":"BMC Cancer"},{"key":"key20180107215106_b15-or-29-06-2486","doi-asserted-by":"crossref","first-page":"2858","DOI":"10.1172\/JCI37539","article-title":"Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus","volume":"120","author":"Di Nicolantonio","year":"2010","journal-title":"J Clin Invest"},{"key":"key20180107215106_b16-or-29-06-2486","doi-asserted-by":"crossref","first-page":"522","DOI":"10.4161\/cbt.8.6.7690","article-title":"Combined MEK and EGFR inhibition demonstrates synergistic activity in EGFR-dependent NSCLC","volume":"8","author":"Balko","year":"2009","journal-title":"Cancer Biol Ther"},{"key":"key20180107215106_b17-or-29-06-2486","first-page":"2316","article-title":"Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways","volume":"9","author":"Janmaat","year":"2003","journal-title":"Clin Cancer Res"},{"key":"key20180107215106_b18-or-29-06-2486","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.humpath.2010.05.025","article-title":"Paradigm of kinase-driven pathway downstream of epidermal growth factor receptor\/Akt in human lung carcinomas","volume":"42","author":"Dobashi","year":"2011","journal-title":"Human Pathol"},{"key":"key20180107215106_b19-or-29-06-2486","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1126\/science.1199484","article-title":"Phosphoproteomic analysis identifies Grb10 as an mTORC1 substrate that negatively regulates insulin signaling","volume":"332","author":"Yu","year":"2011","journal-title":"Science"},{"key":"key20180107215106_b20-or-29-06-2486","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1126\/science.1199498","article-title":"The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling","volume":"332","author":"Hsu","year":"2011","journal-title":"Science"},{"key":"key20180107215106_b21-or-29-06-2486","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1158\/1535-7163.MCT-05-0068","article-title":"Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor\/insulin receptor substrate-1\/phosphatidylinositol 3-kinase cascade","volume":"4","author":"Shi","year":"2005","journal-title":"Mol Cancer Ther"},{"key":"key20180107215106_b22-or-29-06-2486","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1158\/1535-7163.101.4.1","article-title":"Combination therapy of inhibitors of epidermal growth factor receptor\/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition","volume":"4","author":"Goudar","year":"2005","journal-title":"Mol Cancer Ther"},{"key":"key20180107215106_b23-or-29-06-2486","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1038\/sj.bjc.6602646","article-title":"Synergistic growth inhibition by Iressa and rapamycin is modulated by VHL mutations in renal cell carcinoma","volume":"92","author":"Gemmill","year":"2005","journal-title":"Br J Cancer"},{"key":"key20180107215106_b24-or-29-06-2486","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1097\/JTO.0b013e3181ec1531","article-title":"Phase II trial of gefitinib and everolimus in advanced non-small cell lung cancer","volume":"5","author":"Price","year":"2010","journal-title":"J Thorac Oncol"},{"key":"key20180107215106_b25-or-29-06-2486","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.bcp.2009.04.033","article-title":"Everolimus restores gefitinib sensitivity in resistant non-small cell lung cancer cell lines","volume":"78","author":"La Monica","year":"2009","journal-title":"Biochem Pharmacol"},{"key":"key20180107215106_b26-or-29-06-2486","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1097\/JTO.0b013e31820a3a6b","article-title":"Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer","volume":"6","author":"Vienna","year":"2011","journal-title":"J Thorac Oncol"},{"key":"key20180107215106_b27-or-29-06-2486","first-page":"2627","article-title":"Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small cell lung, pancreatic, colon, and breast tumors","volume":"5","author":"Elizabeth","year":"2006","journal-title":"Mol Cancer Ther"},{"key":"key20180107215106_b28-or-29-06-2486","first-page":"189","article-title":"Mechanisms underlying resistance to cetuximab in the HNSCC cell line: role of AKT inhibition in by passing this resistance","volume":"38","author":"Magali","year":"2011","journal-title":"Int J Oncol"},{"key":"key20180107215106_b29-or-29-06-2486","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1182\/blood-2008-10-184515","article-title":"Protein synthesis is resistant to rapamycin and constitutes a promising therapeutic target in acute myeloid leukemia","volume":"114","author":"Tamburini","year":"2009","journal-title":"Blood"},{"key":"key20180107215106_b30-or-29-06-2486","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1172\/JCI44026","article-title":"PIK3CA and KRAS mutations predict for response to everolimus therapy: now that's RAD001","volume":"120","author":"Mohseni","year":"2010","journal-title":"J Clin Invest"}],"container-title":["Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/spandidos-publications.com\/10.3892\/or.2013.2357\/download","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,30]],"date-time":"2023-06-30T12:25:18Z","timestamp":1688127918000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.spandidos-publications.com\/10.3892\/or.2013.2357"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,3,22]]},"references-count":30,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2013,3,22]]},"published-print":{"date-parts":[[2013,6]]}},"alternative-id":["10.3892\/or.2013.2357"],"URL":"https:\/\/doi.org\/10.3892\/or.2013.2357","relation":{},"ISSN":["1021-335X","1791-2431"],"issn-type":[{"value":"1021-335X","type":"print"},{"value":"1791-2431","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,3,22]]}}}